Italfarmaco, a flexible industrial model
News in the field of neuromuscular disorders
Italfarmaco, a flexible industrial model
News in the field of neuromuscular disorders
Two innovations concerning the treatment of serious neuromuscular diseases (Amyotrophic Lateral Sclerosis and Duchenne Muscular Dystrophy) are presented by the Chief Medical Officer of the Italfarmaco Group, Paolo Bettica. The event offers the opportunity for the Group CEO, Paolo Zambonardi, to underline that these results are the effect of a flexible and articulated business strategy, based on sectors of activity apparently irreconcilable but in reality synergistic: basic research and “incremental innovation”.
Two innovations concerning the treatment of serious neuromuscular diseases (Amyotrophic Lateral Sclerosis and Duchenne Muscular Dystrophy) are presented by the Chief Medical Officer of the Italfarmaco Group, Paolo Bettica. The event offers the opportunity for the Group CEO, Paolo Zambonardi, to underline that these results are the effect of a flexible and articulated business strategy, based on sectors of activity apparently irreconcilable but in reality synergistic: basic research and “incremental innovation”.
Italfarmaco, a flexible industrial model
ALS: liquid suspension of Riluzole to facilitate swallowing
it
Paolo Bettica
Givinostat for Duchenne Dystrophy: data from the EPIDYS study
it
Paolo Bettica
Italfarmaco, between basic research and incremental innovation
it
Paolo Zambonardi
Italfarmaco's commitment against Duchenne's Dystrophy
it
Paolo Zambonardi
The food supplements phenomenon. The specificity of the Italfarmaco approach
it
Paolo Zambonardi